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Abstract 
Aβ immunisation of Alzheimer’s disease (AD) patients in the AN1792 (Elan Pharmaceuticals) trial 
caused Aβ removal and a decreased density of neurons in the cerebral cortex. As preservation of 
neurons may be a critical determinant of outcome after Aβ immunisation, we have assessed the impact 
of previous Aβ immunisation on the expression of a range of apoptotic proteins in post-mortem human 
brain tissue. Cortex from 13 AD patients immunised with AN1792 (iAD) and from 27 non-immunised 
AD (cAD) cases was immunolabelled for pro-apoptotic proteins implicated in AD pathophysiology: 
phosphorylated c-Jun N-terminal kinase (pJNK), activated caspase3 (a-casp3), phosphorylated GSK3β 
on tyrosine 216 (GSK3βtyr216), p53 and Cdk5/p35. Expression of these proteins was analysed in 
relation to immunisation status and other clinical data. The antigen load of all of these pro-apoptotic 
proteins was significantly lower in iAD than cAD (p < 0.0001). In cAD, significant correlations (p < 
0.001) were observed between: Cdk5/p35 and GSK3βtyr216; a-casp3 and Aβ42; p53 and age at death. In 
iAD, significant correlations were found between GSK3βtyr216 and a-casp3; both spongiosis and 
neuritic curvature ratio and Aβ42; and Cdk5/p35 and Aβ-antibody level. Although neuronal loss was 
increased by immunisation with AN1792, our present findings suggest downregulation of apoptosis in 
residual neurons and other cells. 
 
Keywords: Alzheimer, treatment, anti-amyloid immunotherapy, brain, neurons, impact. 
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INTRODUCTION 
Alzheimer’s disease (AD) is characterized by the accumulation of β-amyloid (Aβ) peptide and 
hyperphosphorylated tau protein, and eventually synaptic and neuronal loss. The pathophysiology of 
the neuronal death remains unclear and controversial. Neuropathological studies have provided 
evidence of apoptotic neuronal death compatible with the slow progression of neuronal degeneration 
(15, 27, 32), in addition to possible deregulated autophagic activity (3, 14, 16, 24, 44). Apoptosis is a 
sequence of programmed events leading to the activation of caspases and cell disintegration (15, 27, 
32), whereas autophagy is an intracellular catabolic process leading to the removal of aggregated 
proteins within cells (22, 28, 38). Both autophagy and apoptosis are highly regulated, play critical 
roles in tissue homeostasis, and tend to be upregulated in response to extracellular or intracellular 
stress and in neurodegenerative diseases (26). In AD, both processes have been extensively studied but 
their contribution to neuronal death remains unclear. Apoptotic cell death in AD may result from an 
imbalance between pro- and anti-apoptotic proteins (15). The expression of several pro-apoptotic 
kinases such as activated GSK3β phosphorylated at tyrosine 216 (GSK3βtyr216) (1, 6, 37), pPKR (6, 7, 
10, 29, 33, 34, 36), pJNK (9, 18, 42, 43), p53 (8) and activated caspase-3 (a-casp3) (2, 15, 17, 41) is 
increased in AD brains. In AD, autophagic activity is increased but may be dysfunctional, with failure 
of substrate clearance reflected by the presence of vacuoles (3, 14, 16, 24, 44). 
Active Aβ42 immunisation (AN1792, Elan Pharmaceuticals) in AD patients led to Aβ removal (19, 30, 
31) associated with a decrease in phosphorylated tau (pTau) (4), long-term down-regulation of 
inflammation (46), reduction in the number of neurons and reduced neuritic abnormalities (34, 39). To 
investigate possible mechanisms underlying the observed neuronal loss after immunotherapy, we have 
explored the expression of apoptotic and autophagic proteins in the unique cohort of immunised AD 
patients from the AN1792 trial.  
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MATERIALS AND METHODS  
Case selection  
Immunised AD cases (iAD) 
The brains of clinical AD patients enrolled in the initial Elan Pharmaceuticals Aβ immunisation trial 
AN1792 (19) were obtained following consent to post-mortem neuropathology. The study received 
ethical approval from Southampton and South West Hampshire Local Research Ethics Committees 
(Reference No: LRC 075/03/w). Thirteen post-mortem brains in which the cause of the dementia was 
confirmed as AD neuropathologically were included in this study.  All patients had received Aβ42 plus 
adjuvant and had died between 4 and 162 months after the first immunisation (mean 72.8 months, 
median 63 months), with Braak tangle stage V/VI disease, as previously described (34) (Table 1). The 
post-mortem delay was between 6 and 48 hours (mean 18.5 hours; median 6 hours). In addition to 
dementia, the most common clinical diagnoses recorded in the death certificate were 
bronchopneumonia, cerebrovascular accident and myocardial infarction. Other diagnoses included 
ruptured aortic aneurysm, pulmonary embolism, carcinoma of the breast, carcinoma of the bronchus, 
and carcinoma of the pancreas. Neurodegenerative pathology was assessed by standard histological 
methods including haematoxylin and eosin (H&E), Luxol fast blue/cresyl violet and modified 
Bielschowsky silver impregnation. Selected sections were immunolabelled for Aβ, tau, α-synuclein 
and TDP43 to confirm AD.   
 
Non-Immunised AD cases (cAD) 
Twenty-seven AD cases provided by the South West Dementia Brain Bank (SWDBB, Bristol, UK) 
were identified and used as a control unimmunised AD cohort (supplementary Table 1). All cAD cases 
had a clinical diagnosis of AD made during life by an experienced clinician, a Mini-Mental State 
Examination score of <17 prior to death and satisfied post-mortem neuropathological Consensus 
Criteria for Alzheimer’s disease (20). The post-mortem delay was between 9 and 110 hours (mean 39 
hours, median 26 hours). The immunised and control AD cases were matched as closely as possible 
for age, gender, duration of dementia and APOE genotype (Table 1). The SWDBB tissue was used 
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under the ethical approval from North Somerset and South Bristol Hampshire Local Research Ethics 
Committees (Reference No: REC 08/H0106/28+5). 
 
Immunohistochemistry  
Middle temporal gyrus, usually markedly affected by AD pathology, was investigated in this study. 
Four-µm sections of formalin-fixed paraffin-embedded tissue from iAD and cAD cases were 
immunolabelled together in batches to ensure comparability of staining.  
Primary antibodies and immunohistochemistry  
To evaluate the impact of active AN1792 immunisation on apoptotic and autophagic pathways, we 
explored by immunohistochemistry the expression of the following pro-apoptotic proteins: GSK3βtyr216 
(polyclonal rabbit anti-phosphorylated GSK3βtyr216, #ab75745, Abcam) (6, 37), neuron-specific 
activator of cyclin-dependent kinase 5 with its activator p35 (C-19 polyclonal rabbit anti-Cdk5/p35, 
#sc-820, Santa Cruz) (12, 42), phosphorylated c-Jun N-terminal kinase (monoclonal rabbit anti-pJNK 
Thr183/Tyr185, clone 81E11, #4668, Cell Signaling) (18, 45), p53 (monoclonal mouse anti-p53, clone 
DO-1, #sc-126, Santa Cruz) (8), and a-casp3 (polyclonal rabbit anti-activated caspase 3 (Asp175), # 
9661, Cell Signaling) (15, 40, 41); and of the autophagic proteins ATG5 (initial step) (polyclonal 
rabbit anti-ATG5, #AP1812b, Abgent) and microtubule-associated protein light chain LC3-II (a 
marker of the final stage reflecting efficient autophagic activity) (polyclonal rabbit anti- LC3-II, 
#AP1801a, Abgent) (21, 22, 28). The specificity of the antibodies pJNK (18), GSK3βtyr216 (1), and 
CDK5/p35 (21) was previously demonstrated. In order to demonstrate the specificity of the antibodies 
p53, ATG5 and LC3II, we performed western blot on human brain tissue homogenates.  
Immunohistochemistry was carried out by a standard method as previously described (1, 4, 5, 19, 30, 
34, 46). Biotinylated secondary antibodies, normal serum and avidin-biotin complex were from Vector 
Laboratories (Peterborough, UK). Immunodetection was performed using the avidin-biotin-peroxidase 
complex method (Vectastain Elite ABC, UK) with 3,3’-diaminobenzidine (DAB) as chromogen and 
0.05% hydrogen peroxide as substrate. All the sections were dehydrated before mounting in DePeX 
(BDH Laboratory Supplies, UK). Sections from which the primary antibody was omitted were 
included in each immunohistochemistry run. 
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Quantification of immunolabelling 
Quantification was performed blind to the identity of the cases. Thirty fields of cortical grey matter at 
objective magnification x20 were acquired for each case from the same anatomical regions in a zigzag 
sequence along the cortical ribbon to ensure that all cortical layers were represented. Slides were 
marked by the same neuropathologist to ensure consistency in the location of acquisition of the 
images. Protein 'load' defined as the percentage of the field immunopositive for the marker of interest 
was determined using ImageJ (developed by W.S. Rasband National Institutes of Health, Bethesda 
MD, USA, version 1.47g), as in our previous studies (1, 4, 5, 19, 34, 46). 
 
Statistical analysis 
The normality of distribution of each marker across the cohort was assessed by examination of 
quantile-quantile plots (not shown). Levels of each marker were compared between cAD and iAD 
cases in two-sample two-sided t-tests or non-parametric Mann-Whitney U-tests (depending on the 
normality of the data). In both groups, correlations were analysed by Pearson's or Spearman's test, 
depending on the normality of distribution of the markers. We analysed the correlation between the 
apoptosis and autophagy-associated markers and (i) indicators of disease severity and neuronal 
integrity as reported in our previous published studies as follows: Aβ42 load, pTau load, tangles density 
by image, dystrophic neurites, spongiosis, number neuronal NeuN+ density by image, neuritic 
curvature ratio assessed by neurofilament immunohistochemistry, phosphorylated (p)PKR (a marker 
of early neurodegeneration) (4, 19, 34, 46); and (ii) available clinical indicators of disease course and 
antibody response – duration of dementia, survival time after immunisation, age at death, mean and 
peak antibody level. The threshold for statistical significance was set at 5% for intergroup 
comparisons and 1% for correlations, as determined by use of SPSS 21.0.  
 
This article is protected by copyright. All rights reserved.
Paquet et al. 7 
RESULTS  
The immunolabelling of all of the antigens was neuronal, with additional labelling of glial cells for 
some proteins as described in Table 2. Of note, the immunolabelling of activated-caspase 3 was 
cytoplasmic with the nuclei of the stained neurons morphologically normal, without the karyorrhexis 
classically associated with apoptosis. 
The expression of all apoptotic kinases was significantly lower in iAD than cAD cases: a-casp3 load, 
P<0.001; Cdk5/p35 load, P=0.013; p53 load, P<0.001; GSK3βtyr216 load, P<0.01; and pJNK, P<0.001 
(Figure 1). Of the two autophagic markers examined, LC3-II load was significantly lower in iAD than 
cAD (P<0.001) while ATG5 load did not differ between the cohorts (P=0.130, Figure 1).  
The expression of apoptotic and autophagic markers was analysed for correlation with other aspects of 
AD pathology (Aβ42 load, pTau load, dystrophic neurite counts, spongiosis, NeuN+ neurons and 
curvature ratio) in the same anatomical region, and also with a range of clinical parameters (age, 
gender, age at death, dementia duration, peak antibody, survival time). We did not observe any 
modification in the distribution of the proteins between both cohorts except for the GSK3βtyr216, which 
was detected mainly in granulo-vacular degeneration (GVD) in the iAD group but not in the cAD 
group. To take account of possible variations in neuronal density, we also assessed the percentage of 
all neurons that was immunopositive for a-casp3. This confirmed the striking decrease in neuronal 
expression of a-casp3 in iAD compared with cAD (p<0.0001, data not shown).  
In the cAD group, a-casp3 load correlated positively with Aβ42 (r==0.561, P=0.005), and Cdk5/p35 
correlated positively with pGSK3βtyr216 (r==0.642, P<0.001) (Table 3). Comparison of present findings 
with the clinical data revealed positive correlations between p53 and age at death (r==0.564, P=0.003), 
and between LC3-II and dementia duration (r=0.691, P=0.001) (Table 3). 
Within the iAD cohort, a-casp3 and GSK3βtyr216 correlated positively with severity of spongiosis, a 
marker of neuropil degeneration (r=0.789, P=0.004 and r=0.761, P=0.007 respectively) (Table 2). 
ATG5 correlated negatively with Aβ42 load (r==-0.845, P=0.001) and positively with the curvature 
ratio (abnormal tortuosity of neuritic processes) (r==0.841, P=0.001) (Table 4). Cdk5/p35 correlated 
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positively with peak antibody titre (r=0.840, P<0.001) as well as with mean antibody titre (data not 
shown) (Table 4). 
No other correlation was observed in either group.  
 
DISCUSSION  
Our results suggest that active Aβ immunisation of AD patients modulates apoptosis and some 
autophagic cellular signals, causing downregulation of apoptotic proteins and reduction in the final 
stage of autophagy activity. The decrease of apoptotic protein expression after immunisation could 
have several explanations: 1) Downregulation of apoptosis was a consequence of removal of Aβ, 
consistent with several studies implicating Aβ-induced apoptosis in neuronal death in AD (6, 8). 2) 
The reduction in apoptotic proteins may simply reflect the accelerated loss of damaged neurons after 
immunotherapy, as previously reported by us (34), potentially leaving 'healthier' neurons less affected 
by AD pathophysiology. However, the small magnitude of neuronal loss after immunotherapy (about 
10%) could not be the sole explanation for the substantial decrease in apoptotic protein load (between 
65% and 85%), and analysis of the percentage of all neurons that was immunopositive for a-casp3 
confirmed the marked reduction in neuronal expression of this antigen in iAD. 3) Immunotherapy may 
itself down-regulate apoptotic proteins. Further studies are needed to clarify the cellular and molecular 
processes that underlie these findings. 
The effects of autophagic proteins are less clear-cut. The reduction in LC3II suggests downregulation 
of the later steps of autophagy, potentially explained by reduced metabolic requirement for autophagy 
or perhaps an aborted or dysfunctional autophagic process. Restrictions on tissue availability did not 
allow us to explore this mechanistically. Analysis in animal models may help to clarify the influence 
of immunotherapy on autophagy. 
 
The correlation between a-casp3 and Aβ42 in the cAD group, is in accordance with previous reports 
implicating Aβ42 in neuronal apoptosis (6, 15). The link between Cdk5/p35 with GSK3βtyr216 is also 
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consistent with previous studies implicating these proteins in the pathophysiology of AD, particularly 
in the phosphorylation of Tau protein (13, 23). 
Strikingly different associations were observed in the immunised cohort. The relationship between a-
casp3, GSK3βtyr216 loads and the severity of spongiosis, a marker of neuropil degeneration, strengthen 
the association between these pro-apoptotic proteins and the neuronal loss detected after immunisation 
(34). This may explain the absence of clinical amelioration in these patients (19). Due to the nature of 
the post-mortem study, investigating late-stage of the disease and treatment, we cannot exclude the 
possibility that immunotherapy may have induced an early acute apoptotic phase followed by a more 
quiescent phase several years after the treatment.  
 
The relationship between p53 expression and age at death in the control Alzheimer’s cohort is 
consistent with the documented association between apoptosis and increasing age (11). The increase in 
LC3-II with dementia duration may be part of a pro-survival adaptive response by neurons and glia to 
minimise neurodegeneration (14). After immunisation, the anti-Aβ immune response (mean and peak 
Aβ antibody titre) was strongly associated with Cdk5/p35 expression. Cdk5/p35 signalling is known to 
promote microglial phagocytosis of fibrillar Aβ (25), and the present data are in keeping with the 
enhanced Aβ clearance by phagocytic microglia in the immunised patients who developed an immune 
response (19, 35, 46). However, it should be noted that the highest Cdk5/p35 level in the immunised 
cohort was much lower than that in the control group, consistent with the down-regulation of 
microglial activation that occurs when Aβ has been completely removed (46).  
This study has some limitations, inherent in the use of post-mortem tissue. As previously reported (1, 
4, 5, 19, 30, 34, 46), the number of placebo immunisation cases from which brains could be obtained 
(n=1) was far too low to provide useful data for statistical analysis and thus our study used AD brains 
from patients who were not included in a protocol of immunotherapy, although they were matched as 
closely as possible to the immunised cohort. Furthermore, this was a retrospective observational study 
rather than a prospective experimental study, which limited the range of methodological approaches 
and the comparability of clinical findings. Because this was an end-stage study, it was not possible to 
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explore the temporal relationship between markers of apoptosis or autophagy and neuronal loss, and 
analysis was limited to assessment of the late-stage consequences of immunisation.  
In summary, in this unique human brain series from the first anti-Aβ42 trial, our results suggest that 
anti-Aβ42 immunisation downregulates the expression of several pro-apoptotic proteins in the brain. 
Whilst these changes might be expected to be beneficial, the absence of cognitive benefit suggests that 
they occur too late in the disease process or that other mechanisms are responsible for the neuronal 
death.  
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Abbreviations 
a-casp3    activated caspase 3 
AD     Alzheimer’s disease 
ATG5    autophagy-related gene 5 
Aβ     β-amyloid        
CDK5    cyclin dependent Kinase 5 
GSK3βtyr216    glycogen Synthetase Kinase 3 phosphorylated at tyrosine 216  
iAD     immunised Alzheimer’s Disease brains  
JNK     c-Jun N Terminal Kinase  
LC3    microtubule-associated protein light chain 3 
p53    tumor protein 53 
PKR     double-stranded RNA dependent protein kinase     
 iAD    immunised Alzheimer’s disease brains    
cAD    non-immunised Alzheimer’s disease brains   
pTau     phosphorylated tau 
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Table 1 Characteristics of the immunised (iAD) and non-immunised (cAD) Alzheimer’s disease cohorts 
 
ID case Gender Age Braak stage 
Dementia 
duration 
(years) 
APOE status 
Mean antibody 
response (ELISA 
units) 
Survival time from 
1st injection 
(months) 
Post-mortem 
delay (hours) 
         
iAD1 F 74 VI 6 3.4 1:119 20 48 
iAD2 M 83 V 11 3.3 <1:100 4 6 
iAD3 M 63 VI 6 3.3 <1:100 41 6 
iAD4 F 71 VI 10 3.3 1:4072 44 24 
iAD5 M 81 VI 7 3.4 1:1707 57 6 
iAD6 M 82 VI 6 3.4 1:4374 60 24 
iAD7 M 63 VI 10 3.4 1:6470 64 6 
iAD8 M 81 VI 11 4.4 1:491 63 ? 
iAD9 F 88 VI 11 3.3 1:137 86 24 
iAD10 M 88 VI 12 3.4 1:142 94 6 
iAD11 F 89 VI 15 3.4 1:142 111 ? 
iAD12 F 86 VI 13 4.4 <1:100 141 6 
iAD13 F 75 VI 19 ? 1:221 162 48 
cAD 
(n=28) 
15F:13M 63-88 V/VI 3-17 21ε4+:6 ε4- n/a n/a mean 39 
median 26 
n/a: non-applicable 
?: unknown 
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Table 2: Topographical distribution of the apoptotic and autophagic proteins.  
 
 
cAD Neurons Glial cells 
 Cytoplasm Nuclear Cytoplasm Nuclear 
a-casp3 + - + - 
Cdk5/p35 + - + - 
pJNK +  -            + - 
GSK3βtyr216 + + - - 
P53 + - - - 
LC3 + - +  - 
ATG5 + - - + 
 
 
 
 
iAD Neurons Glial cells 
 Cytoplasm Nuclear Cytoplasm Nuclear 
a-casp3 + - - - 
Cdk5/p35 + - + - 
pJNK + - - - 
GSK3βtyr216 +  + - - 
P53 + - - - 
LC3 + - - - 
ATG5 + - - + 
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Table 3: Results of correlation analyses within the non-immunized AD control group 
 
 pJNK Cdk5/p35 p53 a-casp3 GSK3βtyr216 ATG5 LC3-II 
Aβ42 r=0.141 
p=0.483 
r=-0.238 
p=0.232 
r=0.142 
p=0.497 
r=0.561** 
p=0.005 
r=-0.079 
p=0.696 
r=-0.173 
p=0.399 
r=-0.346 
p=0.090 
 
ptau r=-0.228 
p=0.252 
r=0.178 
p=0.374 
r=0.052 
p=0.804 
r=-0.224 
p=0.303 
r=0.365 
p=0.061 
r=-0.214 
p=0.295 
r=0.060 
p=0.777 
 
tangles r=-0.088 
p=0.662 
r=0.092 
p=0.648 
r=-0.254 
p=0.221 
r=-0.070 
p=0.750 
r=0.008 
p=0.970 
r=-0.387 
p=0.050 
r=-0.046 
p=0.828 
 
dystrophic neurites r=0.157 
p=0.433 
r=0.001 
p=0.998 
r=0.094 
p=0.655 
r=0.068 
p=0.758 
r=-0.010 
p=0.959 
r=-0.235 
p=0.248 
r=0.027 
p=0.898 
 
spongiosis r=-0.181 
p=0.365 
r=0.404 
p=0.037 
r=0.048 
p=0.818 
r=-0.327 
p=0.128 
r=0.166 
p=0.409 
r=0.231 
p=0.256 
r=0.084 
p=0.690 
 
NeuN r=0.008 
p=0.971 
r=-0.039 
p=0.860 
r=0.413 
p=0.063 
r=-0.118 
p=0.610 
r=0.361 
p=0.090 
r=0.232 
p=0.298 
r=0.160 
p=0.489 
 
NFP curvature ratio r=-0.042 
p=0.837 
r=0.180 
p=0.369 
r=0.182 
p=0.383 
r=-0.059 
p=0.790 
r=0.174 
p=0.384 
r=-0.055 
p=0.788 
r=0.134 
p=0.524 
 
pPKR r=-0.267 
p=0.178 
r=0.085 
p=0.673 
r=-0.081 
p=0.701 
r=0.094 
p=0.670 
r=0.337 
p=0.085 
r=0.110 
p=0.593 
r=-0.075 
p=0.723 
 
pJNK  r=0.426 
p=0.027 
r=0.055 
p=0.792 
r=0.177 
p=0.419 
r=0.311 
p=0.115 
r=-0.226 
p=0.266 
r=0.202 
p=0.334 
  
Cdk5/p35   r=0.277 
p=0.18 
r=-0.146 
p=0.505 
r=0.648** 
p<0.001 
r=-0.196 
p=0.338 
r=0.300 
p=0.144 
   
p53    r=0.172 
p=0.457 
r=0.280 
p=0.175 
r=-0.055 
p=0.795 
r=0.319 
p=0.120 
    
a-casp3     r=-0.136 
p=0.536 
r=-0.492 
p=0.020 
r=-0.157 
p=0.496 
     
GSK3βtyr216      r=-0.01 
p=0.927 
r=0.128 
p=0.542 
      
ATG5       r=-0.062 
p=0.770 
       
Age at death r=0.210 
p=0.294 
r=0.289 
p=0.144 
r=0.564** 
p=0.003 
r=0.389 
p=0.0670 
r=0.438 
p=0.022 
r=-0.287 
p=0.156 
r=0.220 
p=0.291 
Dementia duration r=0.057 
p=0.796 
r=0.372 
p=0.080 
r=0.388 
p=0.082 
r=-0.062 
p=0.795 
r=-0.008 
p=0.970 
r=0.049 
p=0.830 
r=0.691 
p=0.001 
 
Peak antibody 
r=0.033 
p=0.914 
r=0.840** 
p<0.001 
r=-0.175 
p=0.569 
r=-0.431 
p=0.142 
r=-0.284 
p=0.348 
r=0.459 
p=0.115 
r=-0.386 
p=0.193 
Survival time r=0.455 
p=0.119 
r=0.162 
p=0.590 
r=-0.077 
p=0.802 
r=0.252 
p=0.406 
r=0.446 
p=0.126 
r=0.280 
p=0.354 
r=0.568 
p=0.043 
 
Bold: ** correlation significant at the 0.01 level (2-tailed). 
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Table 4: Results of correlation analyses within the immunized AD control group 
 pJNK Cdk5/p35 p53 a-casp3 GSK3βtyr216 ATG5 LC3-II 
Aβ42 r=-0.237 
p=0.482 
r=-0.491 
p=0.125 
r=-0.361 
p=0.276 
r=0.413 
p=0.207 
r=0.324 
p=0.331 
r=-0.845** 
p=0.001 
r=0.484 
p=0.131 
ptau r=0.397 
p=0.226 
r=0.082 
p=0.811 
r=0.164 
p=0.629 
r=0.089 
p=0.794 
r=-0.231 
p=0.494 
r=0.036 
p=0.915 
r=-0.174 
p=0.610 
tangles r=0.301 
p=0.368 
r=0.464 
p=0.151 
r=-0.050 
p=0.883 
r=-0.089 
p=0.796 
r=-0.207 
p=0.541 
r=0.155 
p=0.650 
r=-0.507 
p=0.112 
dystrophic neurites r=0.037 
p=0.915 
r=-0.246 
p=0.466 
r=-0.165 
p=0.628 
r=0.667 
p=0.025 
r=0.654 
p=0.029 
r=-0.269 
p=0.424 
r=0.547 
p=0.082 
spongiosis r=0.479 
p=0.136 
r=0.009 
p=0.979 
r=-0.087 
p=0.800 
r=0.789** 
p=0.004 
r=0.761** 
p=0.007 
r=-0.055 
p=0.873 
r=0.128 
p=0.708 
NeuN r=0.662 
p=0.037 
r=-0.353 
p=0.318 
r=0.107 
p=0.769 
r=0.691 
p=0.027 
r=0.337 
p=0.340 
r=0.170 
p=0.638 
r=0.055 
p=0.880 
NFP curvature ratio r=0.448 
p=0.167 
r=0.377 
p=0.253 
r=0.194 
p=0.568 
r=-0.152 
p=0.656 
r=0.137 
p=0.687 
r=0.841** 
p=0.001 
r=-0.418 
p=0.201 
pPKR r=0.201 
p=0.577 
r=-0.564 
p=0.090 
r=0.213 
p=0.555 
r=0.297 
p=0.405 
r=0.258 
p=0.471 
r=-0.176 
p=0.627 
r=0.701 
p=0.024 
pJNK  r=0.11 
p=0.720 
r=0.083 
p=0.788 
r=0.534 
p=0.060 
r=0.078 
p=0.801 
r=0.529 
0 p=.063 
r=-0.300 
p=0.319 
Cdk5/p35   r=-0.223 
p=0.464 
r=-0.049 
p=0.873 
r=0.102 
p=0.739 
r=0.363 
p=0.223 
r=-0.342 
p=0.253 
p53    r=0.052 
p=0.865 
r=-0.233 
p=0.444 
r=0.165 
p=0.589 
r=0.268 
p=0.375 
a-casp3     r=0.546 
p=0.054 
r=-0.165 
p=0.590 
r=-0.069 
p=0.823 
GSK3βtyr216      r=-0.108 
p=0.726 
r=-0.218 
p=0.474 
ATG5       r=-0.303 
p=0.314 
Age at death r=0.512 
p=0.074 
r=-0.502 
p=0.08 
r=-0.029 
p=0.925 
r=-0.080 
p=0.795 
r=0.082 
p=0.791 
r=0.337 
p=0.261 
r=-0.262 
p=0.388 
Dementia duration r=0.119 
p=0.700 
r=-0.125 
p=0.684 
r=-0.297 
p=0.324 
r=0.134 
p=0.661 
r=0.178 
p=0.560 
r=0.008 
p=0.978 
r=-0.292 
p=0.333 
Peak antibody r=0.033 
p=0.914 
r=0.840** 
p<0.001 
r=-0.175 
p=0.569 
r=-0.431 
p=0.142 
r=-0.284 
p=0.348 
r=0.459 
p=0.115 
r=-0.386 
p=0.193 
Survival time r=0.455 
p=0.119 
r=0.162 
p=0.590 
r=-0.077 
p=0.802 
r=0.252 
p=0.406 
r=0.446 
p=0.126 
r=0.280 
p=0.354 
r=0.568 
p=0.043 
Bold: ** correlation significant at the 0.01 level (2-tailed). 
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Figure 1: On the left, illustration of the immunolabeling of pro-apoptotic and autophagic proteins as 
observed in Alzheimer's disease.  On the right, quantification of the proteins in the non-immunised AD (cAD) 
compared to immunised AD (iAD) cases showing a significant decrease in all apoptotic proteins and of LC3II 
after immunisation. Scale bar = 50µm.  
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